Key Points
- CTO Raymond Woo sold 11,112 shares on Nov. 11 at an average price of $12.28 for $136,455; the sale reduced his stake to 167,704 shares (a 6.21% decrease) and follows an identical 11,112‑share sale on Oct. 3 at $12.54.
- CeriBell shares traded around $12.52 midday with a market cap of about $464.5M and a 12‑month range of $10.01–$32.75; the company reported a -$0.37 EPS beat and negative margins and profitability metrics.
- Analysts have a consensus rating of "Moderate Buy" with an average target of $25.17, though recent notes include several price target cuts and one sell rating amid mixed coverage.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 11,112 shares of the firm's stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $12.28, for a total value of $136,455.36. Following the transaction, the chief technology officer owned 167,704 shares in the company, valued at approximately $2,059,405.12. This trade represents a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Raymond Woo also recently made the following trade(s):
- On Friday, October 3rd, Raymond Woo sold 11,112 shares of CeriBell stock. The stock was sold at an average price of $12.54, for a total value of $139,344.48.
CeriBell Stock Performance
CBLL stock traded up $0.03 during midday trading on Friday, hitting $12.52. 44,952 shares of the company traded hands, compared to its average volume of 287,386. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $32.75. The stock has a market capitalization of $464.49 million and a price-to-earnings ratio of -8.29. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The business has a 50 day simple moving average of $12.12 and a 200-day simple moving average of $14.48.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The firm had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current year.
Analyst Ratings Changes
CBLL has been the subject of several research analyst reports. Raymond James Financial started coverage on shares of CeriBell in a research note on Tuesday, October 21st. They set a "strong-buy" rating and a $19.00 target price for the company. TD Cowen decreased their target price on CeriBell from $36.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, November 5th. JPMorgan Chase & Co. cut their price target on CeriBell from $21.00 to $17.00 and set an "overweight" rating for the company in a report on Wednesday, November 5th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of CeriBell in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CeriBell presently has a consensus rating of "Moderate Buy" and an average target price of $25.17.
View Our Latest Analysis on CBLL
Institutional Investors Weigh In On CeriBell
A number of hedge funds have recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in CeriBell during the 1st quarter valued at about $36,000. Tower Research Capital LLC TRC grew its stake in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after buying an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock worth $48,000 after buying an additional 1,256 shares in the last quarter. New York State Common Retirement Fund bought a new position in shares of CeriBell in the first quarter valued at approximately $67,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company's stock worth $106,000 after acquiring an additional 3,502 shares in the last quarter.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
